IRVING, Texas--(BUSINESS WIRE)-- Biote (BTMD) (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, ...
Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...
IRVING, Texas--(BUSINESS WIRE)-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...
Represents cash and non-cash interest on our debt obligations, commitment fees for our unused Revolving Loans, net of interest income earned on our money market account. Interest expense, net, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback